News

Act Now: Join the Class Action Against Moderna, Inc. MRNA

Act Now: Join the Class Action Against Moderna, Inc. MRNA

Join the Class Action Against Moderna, Inc.

The Gross Law Firm has recently announced important information regarding a class action lawsuit against Moderna, Inc. (NASDAQ: MRNA). If you are a shareholder who acquired shares of MRNA during a specific class period, you might be eligible to participate in this significant legal action.

Understanding the Class Action Details

It is vital for shareholders to comprehend the implications of this class action suit. The class period in question runs from January 18, 2023, to June 25, 2024. This period marks a time during which allegations were made against the company regarding misleading statements concerning the efficacy of one of its vaccines, mRNA-1345.

What Are the Allegations?

The primary allegations concern claims that during the specified class period, Moderna made statements about mRNA-1345 that were deemed materially false and misleading. It was alleged that the effectiveness of the vaccine was overstated, leading investors to have a skewed understanding of the company's prospects.

Why is This Important?

The misleading information can severely impact investor confidence and stock performance. It is essential for all shareholders to recognize their rights and the potential for recovery should the court side with the plaintiffs in this class action.

How to Participate in the Class Action

If you believe you qualify based on your share purchases during the class period, you are encouraged to contact The Gross Law Firm. Getting involved is crucial, and there is no obligation or cost to participate in the lawsuit.

Steps to Register

To register, shareholders need to provide their information to the law firm. Once registered, shareholders will gain access to a monitoring software application. This service will keep you informed on the case's developments and your standing throughout the proceedings.

It is important to note that the deadline for registering to be considered as a lead plaintiff is set for October 8, 2024. Acting promptly can enhance your chances for possible recovery.

About The Gross Law Firm

The Gross Law Firm is a highly regarded entity in the field of class action law, focusing on safeguarding investors' rights. Their mission centers on advocating for those impacted by dishonest business practices. This firm's commitment extends to ensuring corporations uphold ethical standards and engage positively with stakeholders.

Expertise You Can Trust

Choosing The Gross Law Firm means aligning with a team that understands the complexities of class action lawsuits. Their dedication to transparency and recovery for investors encourages trust and confidence as they navigate these challenging waters together.

Contact Information

If you need more information, The Gross Law Firm can be reached via the following contact methods:

Address: 15 West 38th Street, 12th floor, New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903

Frequently Asked Questions

What is the class action about?

The class action concerns allegations against Moderna regarding misleading statements about the effectiveness of its vaccine, mRNA-1345.

Who can join the class action?

Shareholders who purchased MRNA shares between January 18, 2023, and June 25, 2024, can join the class action.

What steps should I take to participate?

Interested shareholders should contact The Gross Law Firm to register their information for participation.

Is there a cost to join the lawsuit?

No, there is no cost or obligation to join the class action lawsuit.

What is the deadline for registration?

The deadline to register to be considered for lead plaintiff status is October 8, 2024.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 9

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 8

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 8

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 6

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 3

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
USPS Honors 150 Years of the U.S. Coast Guard Academy

Updated Category News Views 6

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 1

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 5

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 4

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading

Top 5 Most Recently Viewed Articles

Alexander’s Inc. Announces $4.50 Dividend for Shareholders

Updated Category News Views 71

Alexander’s Inc. Declares Impressive Quarterly Dividend In an exciting announcement for investors, Alexander’s, Inc. (NYSE: ALX) has declared a quarterly dividend of $4.50 per share. This significant decision by the Board of Directors highlights the company's ongoing commitment to delivering value to its shareholders. Details of the Dividend Declaration The declared...

Continue Reading
Tachyus and EagleRidge Team Up for Advanced Carbon Solutions

Updated Category News Views 209

Tachyus and EagleRidge Announce Exciting New Partnership Tachyus is thrilled to share some exciting news! The innovative company has recently partnered with EagleRidge Energy to implement Aurion, an advanced platform designed for comprehensive carbon accounting, monitoring, and forecasting. This collaboration marks a significant advancement for both companies as they work...

Continue Reading
Navigating New Cybersecurity Regulations with Mobilicom's Innovations

Updated Category News Views 166

Navigating New Cybersecurity Regulations with Mobilicom's Innovations The U.S. Department of War has introduced the Cybersecurity Risk Management Construct (CSRMC), a significant shift that emphasizes real-time cyber defense for autonomous systems. This new framework highlights the increasing urgency for security measures in military technology, particularly in the areas...

Continue Reading
Revolutionizing Precision Measurement with Kyocera's New Sensor

Updated Category News Views 409

Kyocera Unveils a Game-Changing Depth Sensor Kyocera Corporation has introduced an advanced AI-based high-resolution depth sensor, marking a significant leap in the ability to measure small objects with remarkable precision. This innovative sensor is designed specifically for challenging applications that have previously been difficult to address with existing...

Continue Reading
Novartis Successfully Completes Hart-Scott-Rodino Waiting Period

Updated Category News Views 284

Novartis Completes Hart-Scott-Rodino Waiting Period Novartis recently reached a key milestone in its journey to acquire Tourmaline Bio, Inc., as the waiting period mandated by the Hart-Scott-Rodino Antitrust Improvements Act has officially expired. This crucial step took place at 11:59 p.m. Eastern Time, signaling important progress for the ongoing tender offer aimed at...

Continue Reading